james, Author at ichorbio

Updated 2023 price comparison with Bio X Cell: academic customers can save up to 35% [...]

Updated 2023 price comparison with Bio X Cell: industry customers can save up to 50% [...]

We’re pleased to announce the release of our updated therapeutic antibody sequence report which now [...]

Today is The International Day of Women and Girls in Science and the ichorbio team [...]

ichorbio has just published a list sequences of more than 660 therapeutic antibodies. As far [...]

Wishing all our friends and colleagues throughout Asia a very happy Spring Festival and all [...]

Happy New Year to all our friends and colleagues – we hope that 2023 is [...]

ichorbio has just released a research grade (RUO) biosimilar to Rosopatamab. Rosopatamab Biosimilar – Research [...]

July is sarcoma and bone cancer awareness month so we’ve created a simple infographic with [...]

July is ultraviolet (UV) safety month and so we’ve created an infographic with more information [...]

Solid tumors contain abnormal and heterotypic cells that communicate through tight and gap junctions. In [...]

All Antibodies Approved or in Clinical Trials ichorbio has created an editable spreadsheet that we [...]

Non-small cell lung cancer (NSCLC) is the most common lung cancer. There are three main [...]

Psoriasis is a skin disease that causes red, itchy scaly patches, most commonly on the [...]

ichorbio has created a document on how to write a great life science paper which [...]

ichorbio is pleased to release our new and updated flyer for all of our different [...]

ichorbio released a research grade (RUO) version of the biosimilar Durvalumab on 18th November 2021. [...]

ichorbio has released five new biosimilars targeting PD-1 and PD-L1. The biosimilars are as follows: [...]

Today, ichorbio is excited to announce the release of our second mouse anti-mouse recombinant antibody. [...]

Today, ichorbio is excited to announce the release of our first mouse anti-mouse recombinant antibody. [...]